Streetbeat News

DRUG

Bright Minds Biosciences Inc.

https://brightmindsbio.com

Industry

Biotechnology

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

Open

39.50

Mkt cap

285M

Volume

154K

High

42.50

P/E Ratio

-66.13

52-wk high

79.02

Low

39.50

Div yield

N/A

52-wk low

0.93

Cumberland Pharmaceuticals has received FDA Orphan Drug and Rare Pediatric Disease designations for Ifetroban, a treatment for cardiomyopathy associated with Duchenne muscular dystrophy.

Portfolio Pulse from

November 06, 2024 | 10:30 pm

Bright Minds Biosciences (NASDAQ:DRUG) shares are trading higher following a new collaboration with Firefly Neuroscience for EEG data analysis in their BREAKTHROUGH study. The stock previously soared 1,445% in a day, despite no specific news, and announced a private placement for R&D funding.

Portfolio Pulse from Adam Eckert

October 21, 2024 | 2:33 pm

Bright Minds Biosciences experienced a trading halt due to a circuit breaker triggered by a sharp decline. However, the stock rebounded and is now up by 13.7%.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 1:56 pm

Bright Minds Biosciences shares were halted due to a circuit breaker as the stock surged 27%.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 1:44 pm

Firefly Neuroscience and Bright Minds Biosciences shares are trading higher following their collaboration announcement to analyze EEF data in the BREAKTHROUGH trial.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 1:36 pm

Bright Minds Biosciences shares rose following the announcement of a collaboration with Firefly Neuroscience to analyze EEG data in the BREAKTHROUGH study.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 12:55 pm

Bright Minds Biosciences has announced a collaboration with Firefly Neuroscience to analyze EEF data in their BREAKTHROUGH trial. This partnership aims to enhance the understanding of the trial's outcomes.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 12:43 pm

Bright Minds Biosciences Inc. announced a non-brokered private placement to raise up to $35 million through the sale of common shares and pre-funded warrants. The funds will be used for drug development and general working capital.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 9:14 am

U.S. stocks mostly rose with the Nasdaq gaining over 100 points. Schlumberger reported mixed Q3 results, missing revenue expectations but beating EPS estimates. United States Cellular sold spectrum licenses to Verizon, boosting its stock. Bright Minds Biosciences surged after a private placement announcement. MGP Ingredients and CVS Health saw declines due to soft guidance and outlook cuts, respectively.

Portfolio Pulse from Avi Kapoor

October 18, 2024 | 6:15 pm

U.S. stocks mostly rose with the Nasdaq gaining 100 points. American Express shares fell 5% after Q3 results, missing revenue estimates but beating EPS. United States Cellular surged 12% on a spectrum sale to Verizon. Bright Minds Biosciences soared 196% after a private placement. MGP Ingredients dropped 26% on weak guidance. CVS Health fell 8% after cutting its Q3 outlook.

Portfolio Pulse from Avi Kapoor

October 18, 2024 | 4:29 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.